Nektar Therapeutics (NASDAQ:NKTR)’s traded shares stood at 3.26 million during the last session, with the company’s beta value hitting 0.71. At the close of trading, the stock’s price was $1.35, to imply a decrease of -9.40% or -$0.14 in intraday trading. The NKTR share’s 52-week high remains $1.75, putting it -29.63% down since that peak but still an impressive 69.63% since price per share fell to its 52-week low of $0.41. The company has a valuation of $247.89M, with an average of 2.32 million shares over the past 3 months.
Nektar Therapeutics (NASDAQ:NKTR) trade information
After registering a -9.40% downside in the last session, Nektar Therapeutics (NKTR) has traded red over the past five days. The stock hit a weekly high of 1.7500, dropping -9.40% in its intraday price action. The 5-day price performance for the stock is 4.65%, and 58.82% over 30 days. With these gigs, the year-to-date price performance is 138.94%.
Nektar Therapeutics (NKTR) estimates and forecasts
Looking at statistics comparing Nektar Therapeutics share performance against respective industry, we note that the company has outperformed competitors. Nektar Therapeutics (NKTR) shares are 156.17% up over the last 6 months, with its year-to-date growth rate higher than industry average at 32.41% against 9.70%. Revenue is forecast to grow 74.00% this quarter before jumping 29.60% for the next one. The rating firms project that company’s revenue will shrink -25.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $15.34 million. Meanwhile, for the quarter ending Jun 2024, a total of 3 analyst(s) estimate revenue growth to $15.34 million.Earnings reports from the last fiscal year show that sales brought in -$ and $20.5 million respectively in the corresponding quarters.
NKTR Dividends
Nektar Therapeutics has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Nektar Therapeutics has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
